Immunovaccine is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery platform and product candidates for therapeutic cancer indications and infectious diseases.
Key Highlights
• DepoVax platform is capable of enhancing a range of vaccines in infectious disease and therapeutic cancer
• Two therapeutic cancer vaccines in clinical tirals: DPX-Survivac and DPX-0907 with early positive results
• Established commercial scale manufacturing process
• Broad patents issued in the US, EU, AU and Asia
• Licensing deals with Pfizer to develop new vaccines for livestock
• Secured non-dilutive government funding of $2.9M from the Atlantic Innovation Fund
• Signed several early research agreements with companies and academic institutions interested in enhancing their vaccines with DepoVax
